Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies | Global News Avenue

Sarepta Therapeutics (SRPT) reported that patients taking thyroid muscular dystrophy died of acute liver failure (ALF). The news stock price fell 23%.

The pharmaceutical company noted that “acute liver injury is a known side effect of Class A-grade organisms” and other similar gene therapies, although this is the first time anyone has reported death from taking the drug.

Sarepta explained that the patient had a recent cytomegalovirus (CMV) infection, which was “determined by the treatment physician as a possible contributor.”

The company said it continues to collect and analyze information from the incidents and has reported it to health authorities. Sarepta also plans to update its prescription information to “denote this event appropriately.”

Investopedia The company has been contacted to see if any other action may be considered.

Including the sharp decline today, Sarepta Therapeutics stock lost more than 35% of its value last year.